Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
METI Seeks 7.2 Bil. Yen for Drug Discovery, 3.5 Bil. for Regenerative Medicine
The Ministry of Economy, Trade and Industry (METI) is seeking 673.3 billion yen in science-related budgets for FY2017, beginning next April, compared to the 545.8 billion yen initial budget allocated in FY2016. METI’s total budget request, released on August 31,…
To read the full story
Related Article
- Govt Health Promotion Taskforce Seeks 152.8 Billion Yen for AMED
September 1, 2016
- MHLW to Set Up Dedicated Office for Antimicrobial Resistance: FY2017 Budget
August 24, 2016
- MHLW to Seek 2 Billion Yen to Foster Healthcare Startups in FY2017
August 24, 2016
- MHLW to Seek Funding to Promote and Support Healthcare Startups in FY2017 Budget Request
August 23, 2016
- MHLW to Seek Budgets to Develop Artificial Intelligence for Drug Discovery
August 22, 2016
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Health Minister Signals Early March Approval for iPSC Products
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…